Potential therapeutic marker, ERBB4, located on chromosome 2q34, promotes tumor growth in ER-positive breast cancer. Other associated cancers include, lung, prostate, colon, liver, and esophageal.

Empire Genomics has developed a custom ERBB4 probe which can be used to detect/confirm a rearrangement of the ERBB4 gene. The probe comes labeled in orange, and you may also choose to customize the probe to meet your needs.

 

** This product is for in vitro and research use only. This product is not intended for diagnostic use.

Gene Summary

This gene is a member of the Tyr protein kinase family and the epidermal growth factor receptor subfamily. It encodes a single-pass type I membrane protein with multiple cysteine rich domains, a transmembrane domain, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. Mutations in this gene have been associated with cancer. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized. [provided by RefSeq, Jul 2008]

Gene Details

Gene Symbol: ERBB4

Gene Name: Erb-b2 Receptor Tyrosine Kinase 4

Chromosome: CHR2: 212240441-213403352

Locus: 2q34

References

Next-Generation Sequencing to Detect Deletion of RB1 and ERBB4 Genes in Chromophobe Renal Cell Carcinoma: A Potential Role in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma

Chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO) are two tumors that are difficult to distinguish from one another. It is important to distinguish them because ChRCC is a malignant tumor whereas RO is a benign tumor. Deletion of the RB1 and ERBB4 genes are indicative of ChRCC because these are tumor-suppressant genes. FISH analysis was used to identify these deletions. Our dual color probes were used that targeted RB1-Orange (MAC clone RP11-893E5) and 13q11-Green (RP11-408E5). A green ERBB4 probe was also used.

The Utility of ERBB4 and RB1 Immunohistochemistry in Distinguishing Chromophobe Renal Cell Carcinoma From Renal Oncocytoma

Renal oncocytoma (RO) is a benign epithelial neoplasm that makes up about 5 to 9% of all renal cell tumors. RO can be difficult to distinguish from a closely related but malignant counterpart, chromophobe renal cell carcinoma (ChrCC). This study used both IHC and FISH to detect the presence of RB1 and ERBB4, two genes that have been found deleted in ChrCC but not RO. A total of 28 ChrCCs and 25 RO cases were tested. Empire Genomics’ RB1 and ERBB4 FISH probes were used to detect deletions in these genes.